JP2005527227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527227A5 JP2005527227A5 JP2004508560A JP2004508560A JP2005527227A5 JP 2005527227 A5 JP2005527227 A5 JP 2005527227A5 JP 2004508560 A JP2004508560 A JP 2004508560A JP 2004508560 A JP2004508560 A JP 2004508560A JP 2005527227 A5 JP2005527227 A5 JP 2005527227A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- interest
- ligand
- expression
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 32
- 125000003729 nucleotide group Chemical group 0.000 claims 32
- 238000000034 method Methods 0.000 claims 23
- 230000000903 blocking effect Effects 0.000 claims 20
- 238000013518 transcription Methods 0.000 claims 20
- 230000035897 transcription Effects 0.000 claims 20
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 239000003446 ligand Substances 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 108020001756 ligand binding domains Proteins 0.000 claims 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102100039556 Galectin-4 Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 1
- 241000701489 Cauliflower mosaic virus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 108010001515 Galectin 4 Proteins 0.000 claims 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102000003792 Metallothionein Human genes 0.000 claims 1
- 108090000157 Metallothionein Proteins 0.000 claims 1
- 241000713333 Mouse mammary tumor virus Species 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 claims 1
- 241000714474 Rous sarcoma virus Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 108010085012 Steroid Receptors Proteins 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108010079892 phosphoglycerol kinase Proteins 0.000 claims 1
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 1
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 1
- 102000005969 steroid hormone receptors Human genes 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 102000004217 thyroid hormone receptors Human genes 0.000 claims 1
- 108090000721 thyroid hormone receptors Proteins 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38400402P | 2002-05-29 | 2002-05-29 | |
| US60/384,004 | 2002-05-29 | ||
| PCT/US2003/016676 WO2003101189A1 (en) | 2002-05-29 | 2003-05-28 | Inducible eukaryotic expression system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011110860A Division JP2011152152A (ja) | 2002-05-29 | 2011-05-17 | 誘導性の真核生物発現システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005527227A JP2005527227A (ja) | 2005-09-15 |
| JP2005527227A5 true JP2005527227A5 (https=) | 2006-06-01 |
| JP4817657B2 JP4817657B2 (ja) | 2011-11-16 |
Family
ID=29711966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508560A Expired - Lifetime JP4817657B2 (ja) | 2002-05-29 | 2003-05-28 | 誘導性の真核生物発現システム |
| JP2011110860A Withdrawn JP2011152152A (ja) | 2002-05-29 | 2011-05-17 | 誘導性の真核生物発現システム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011110860A Withdrawn JP2011152152A (ja) | 2002-05-29 | 2011-05-17 | 誘導性の真核生物発現システム |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7455988B2 (https=) |
| EP (1) | EP1531666B1 (https=) |
| JP (2) | JP4817657B2 (https=) |
| AU (1) | AU2003237259B2 (https=) |
| BR (1) | BRPI0311201B1 (https=) |
| CA (1) | CA2485939C (https=) |
| DK (1) | DK1531666T3 (https=) |
| ES (1) | ES2439874T3 (https=) |
| MX (1) | MXPA04011679A (https=) |
| WO (1) | WO2003101189A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9379801A (en) * | 2000-09-09 | 2002-03-22 | Basf Plant Science Gmbh | Modified tet-inducible system for regulation of gene expression in plants |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| EP1687017B1 (en) | 2003-10-24 | 2013-03-06 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| GB0418651D0 (en) * | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| KR101441843B1 (ko) * | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법 |
| WO2010089387A1 (en) | 2009-02-09 | 2010-08-12 | Morphosys Ag | Production of oligoclonal mixtures of immunoglobulins in single cells |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| CN104211814A (zh) | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | 用于消耗靶膜蛋白的组合物 |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| EP3411483B1 (en) * | 2016-02-05 | 2022-07-06 | PolyGene AG | Glucocorticoid-based gene regulation system |
| EA201892137A1 (ru) | 2016-04-20 | 2019-03-29 | Регенерон Фармасьютикалз, Инк. | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию |
| US11512144B2 (en) | 2016-04-20 | 2022-11-29 | Regeneran Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing loci |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| WO2022216825A1 (en) * | 2021-04-06 | 2022-10-13 | Senti Biosciences, Inc. | Ert2 mutants and uses thereof |
| EP4320228A4 (en) * | 2021-04-06 | 2025-07-02 | Senti Biosciences Inc | ERT2 MUTANTS AND THEIR USES |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| MX2024004691A (es) * | 2021-10-18 | 2024-05-23 | Regeneron Pharma | Transcripcion controlada de polinucleotidos. |
| WO2023167847A2 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Bioreactor for antibody production |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5756448A (en) * | 1992-02-26 | 1998-05-26 | The General Hospital Corporation | Constitute activator of retinoid (CAR) receptor polypeptides |
| US5866755A (en) * | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
| US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| JPH09500526A (ja) * | 1993-06-14 | 1997-01-21 | ベーアーエスエフ アクツィエンゲゼルシャフト | テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御 |
| GB2301991B (en) * | 1995-06-06 | 1999-06-30 | Plessey Telecomm | SDH Network |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US5739018A (en) * | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
| US5972650A (en) * | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6117680A (en) * | 1997-08-26 | 2000-09-12 | Ariad Gene Therapeutics, Inc. | Compositions and methods for regulation of transcription |
| US6153383A (en) * | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
| FR2782732A1 (fr) * | 1998-08-28 | 2000-03-03 | Transgene Sa | Systeme d'expression inductible |
| US7329728B1 (en) * | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| FR2814642B1 (fr) * | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| WO2002062949A2 (en) * | 2000-10-20 | 2002-08-15 | Canji, Inc | Aptamer-mediated regulation of gene expression |
| US20040102367A1 (en) * | 2001-02-23 | 2004-05-27 | Gage Fred H | Gene expression system based on chimeric receptors |
| US7153685B2 (en) * | 2002-03-11 | 2006-12-26 | The Board Of Trustees Of The University Of Illinois | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells |
-
2003
- 2003-05-28 CA CA2485939A patent/CA2485939C/en not_active Expired - Lifetime
- 2003-05-28 DK DK03736725.7T patent/DK1531666T3/da active
- 2003-05-28 BR BRPI0311201-2A patent/BRPI0311201B1/pt not_active IP Right Cessation
- 2003-05-28 JP JP2004508560A patent/JP4817657B2/ja not_active Expired - Lifetime
- 2003-05-28 MX MXPA04011679A patent/MXPA04011679A/es active IP Right Grant
- 2003-05-28 WO PCT/US2003/016676 patent/WO2003101189A1/en not_active Ceased
- 2003-05-28 ES ES03736725.7T patent/ES2439874T3/es not_active Expired - Lifetime
- 2003-05-28 AU AU2003237259A patent/AU2003237259B2/en not_active Expired
- 2003-05-28 US US10/447,243 patent/US7455988B2/en not_active Expired - Lifetime
- 2003-05-28 EP EP03736725.7A patent/EP1531666B1/en not_active Expired - Lifetime
-
2006
- 2006-01-13 US US11/332,431 patent/US7514545B2/en not_active Expired - Lifetime
-
2011
- 2011-05-17 JP JP2011110860A patent/JP2011152152A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527227A5 (https=) | ||
| US5648267A (en) | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | |
| Ye et al. | Robust CRISPR/Cas9 mediated genome editing and its application in manipulating plant height in the first generation of hexaploid Ma bamboo (Dendrocalamus latiflorus Munro) | |
| Yé lamos et al. | Targeting of non-lg sequences in place of the V segment by somatic hyper mutation | |
| Xie et al. | Suppression or knockout of SaF/SaM overcomes the Sa‐mediated hybrid male sterility in rice | |
| US6159730A (en) | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same | |
| Zhang et al. | CRISPR/Cas9-based genome editing in plants | |
| Chowdhury et al. | Stepwise activation of the immunoglobulin μ heavy chain gene locus | |
| Jakobovits et al. | Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs | |
| Agellon et al. | Dietary cholesterol fails to stimulate the human cholesterol 7α-hydroxylase gene (CYP7A1) in transgenic mice | |
| Schlissel | Regulation of activation and recombination of the murine Igκ locus | |
| WO1994011523A9 (en) | Fully impaired consensus kozac sequences for mammalian expression | |
| Palmer et al. | Genetic control of levels of murine kidney glucuronidase mRNA in response to androgen. | |
| WO2015158115A1 (zh) | 一种简便高效的基因编辑方法 | |
| Jackson et al. | Regulation of T cell receptor β allelic exclusion at a level beyond accessibility | |
| DE69942650D1 (de) | Verfahren zum limitieren des herauskreuzens und unerwünschten genflusses in nutzpflanzen | |
| Gomulkiewicz et al. | Evading resistance to gene drives | |
| Robertson et al. | Effects of mouse strain, position of integration and tetracycline analogue on the tetracycline conditional system in transgenic mice | |
| Liu et al. | Past innovations and future possibilities in plant chromosome engineering | |
| Wang et al. | Developing a CRISPR/FrCas9 system for core promoter editing in rice | |
| Prescott et al. | Varied poly (A) site efficiency in the adenovirus major late transcription unit. | |
| Schlissel | Allelic exclusion of immunoglobulin gene rearrangement and expression: why and how? | |
| Salem et al. | Prime editing in mice with an engineered pegRNA | |
| Holmes et al. | Timing and sequence requirements defined for embryonic maintenance of imprinted DNA methylation at Rasgrf1 | |
| CA2426959A1 (en) | Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation |